Evidence map›Paper›PMID 33622120›Full record

ReviewExpert opinion on investigational drugs2021

Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Massimiliano Cadamuro, Alberto Lasagni, Angela Lamarca, Laura Fouassier, Maria Guido, Samantha Sarcognato, Enrico Gringeri, Umberto Cillo, Mario Strazzabosco, Jose Jg Marin and 2 more

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on investigational drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Massimiliano CadamuroDepartment of Molecular Medicine (DMM), University of Padua, Padua. Italy.ORCID https://orcid.org/0000-0002-0899-7613
Alberto LasagniDivision of General Medicine, Padua University-Hospital, Padua, Italy.
Angela LamarcaDepartment of Medical Oncology, The Christie NHS Foundation, Manchester, United Kingdom.
Laura FouassierSorbonne Université, Inserm, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Maria GuidoDepartment of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Samantha SarcognatoDepartment of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Enrico GringeriHepatobiliary Surgery and Liver Transplantation, Padua University-Hospital, Padua, Italy.
Umberto CilloHepatobiliary Surgery and Liver Transplantation, Padua University-Hospital, Padua, Italy.
Mario StrazzaboscoInternational Center for Digestive Health (ICDH), University of Milan-Bicocca, Milan, Italy.
Jose Jg MarinExperimental Hepatology and Drug Targeting (HEVEPHARM), IBSAL, CIBERehd, University of Salamanca, Salamanca, Spain.ORCID https://orcid.org/0000-0003-1186-6849
Jesus M BanalesDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain.
Luca FabrisDepartment of Molecular Medicine (DMM), University of Padua, Padua. Italy.
University of Padua · ITIkerbasque · ESInserm · FRUniversidad de Salamanca · ESUniversity of Manchester · GBYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Liver disease in CF: CFTR controls innate immunity in biliary epitheliumR01DK096096 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2013 to 2022
$4.6M
Cross talk between epithelial, inflammatory and mesenchymal cells in the development of portal fibrosisR01DK101528 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2015 to 2023
$3.5M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK096096NIDDK NIH HHS R01 DK101528
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyBile Duct NeoplasmsCholangiocarcinomaHumansImmunotherapyPrecision MedicinePrognosisTumor MicroenvironmentcholangiocarcinomaCholangiocyteepithelial-to-mesenchymal transitionextrahepatic cholangiocarcinomaimmunotherapymolecularly targeted therapiesoncogenic driverstumor microenvironment

Identifiers

PMID33622120
PMCPMC8194059
OpenAlexW3129311122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.